AZD4635 is an orally bioavailable, potent and selective A2A (Adenosine 2A) receptor antagonist, binding to human A2A receptor with a Ki value of 1.7 nM, and with > 30-fold selectivity over other adenosine receptors. High adenosine level in tumors, produced by stimulating A2A receptors, is immune suppressive, which prevents T-cells within the immune system from being activated thus reduces their ability to destroy cancer cells. Antagonizing A2A receptors can therefore promote the anti-cancer response of T-cells within the tumour microenvironment.

Keywords: AZD4635 | Supplier | A2A antagonist | HTL-1071 | Imaradenant | AZD-4635 | AZD 4635 | HTL1071 | HTL 1071 | CT-A4635 | CAS [1321514-06-0] | Adenosine | A2A | Antagonist | Receptors